SAN DIEGO, Nov. 10, 2010 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present an update on Marshall Edwards and its lead oncology programs at the Lazard Capital Markets Healthcare Conference on Wednesday, November 17, 2010 at 3:15 p.m. EST from the St. Regis New York. A live webcast of the presentation can be accessed at www.marshalledwardsinc.com.
About Marshall Edwards
Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's pipeline is derived from an investigational isoflavone technology platform that has generated a number of compounds with anti-proliferative tumor activity. These small molecules have been shown to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival. The Company's lead programs focus on two families of compounds with related but distinct mechanisms of action. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidates. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.
|SOURCE Marshall Edwards, Inc.|
Copyright©2010 PR Newswire.
All rights reserved